Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"Cervarix"”.
-
Production and immunogenicity of chimaeric human papillomavirus-like particle vaccines
… targeted against HPV -16, -18; -6 and -11, and Cervarix(TM), against -16 and -18. Both vaccines are based on the L1 capsid proteins of the types they are targeted to and are efficient, pro- phylactic, typespecific vaccines. However, two problems remain: they do not protect against nonvaccine …
-
Novel intranasal GNRs-DNA vaccines against human papillomavirus infection
Currently licensed HPV vaccines, Cervarix and Gardasil, have been successfulin preventing HPV infection and high-graded cervical intraepithelial neoplasia (CIN2,3) in school girls in the UK and other developed countries. However, their high costshave hindered their wider use in preventing HPV …
-
HPV pseudovirion production in plants
… of two currently available vaccines, namely Cervarix™ and Gardasil®. Cervarix offers protection against high-risk HPV types 16 and 18, while Gardasil offers further protection against types 6 and 11. Both of these vaccines are based on major capsid protein L1 Virus-like particles (VLPs). …
-
Chlamydia trachomatis diversity and pathogenesis in young South African women, related to HPV prevalence and risk
… while AGYW are currently being vaccinated using Cervarix® vaccine for HPV-16 and HPV-18, the non-HPV-16/18 types commonly found in this cohort argue for the need for a broader vaccination strategy (eg. Gardasil®9). Public health initiatives are needed to be implemented to reduce the burden of …
-
Provider Recommendations for Human Papillomavirus Vaccine (HPV) Among Adolescent Males in Southwest Georgia Counties and The Associated Hpv Prevalence in This Population
<p><strong>Objective:</strong> The purpose of this research study was to examine the variation in healthcare providers’ behavior in recommending the Human Papillomavirus (HPV) vaccine to young male adolescents (aged 11-12), middle male adolescents (aged 13-17) and late male adolescents (aged 18-26) …